Home > News > Abraxis BioScience: A SPARC for Explosive Growth?
July 20th, 2006
Abraxis BioScience: A SPARC for Explosive Growth?
Abstract:
Abraxis BioScience, Inc. (ABBI) provides a unique opportunity for investment in a biopharmaceutical company that is revolutionizing cancer therapy with its proprietary nanotechnology platform. Abraxis’ nanoparticle albumin-bound, or nab technology, exploits the natural properties of a human protein, albumin, for drug delivery.
Source:
seekingalpha.com
Related News Press |
Investments/IPO's/Splits
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018
Nanometrics to Present at the 30th Annual ROTH Conference February 27th, 2018
180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018
Nanomedicine
Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018
Observing biological nanotransporters: Chemistry April 19th, 2018
Nanobiotix Shows NBTXR3 Nanoparticles Can Stoke Anti-Tumor Immune Response April 17th, 2018
Profiles
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |